Nir Uriel

Nir Uriel

Auto-generated profile, based on publicly available information

Nir Uriel

Columbia University Irving Medical Center

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
JFJustin A. Fried
Justin A. Fried
KRKumudha Ramasubbu
Kumudha Ramasubbu
RBReema Bhatt
Reema Bhatt
VTVeli K. Topkara
Veli K. Topkara
KCKevin J. Clerkin
Kevin J. Clerkin
GSGabriel Sayer
Gabriel Sayer

1 October 2020 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
FLFarhana Latif
Farhana Latif
MFMaryjane A. Farr
Maryjane A. Farr
KCKevin J. Clerkin
Kevin J. Clerkin
MHMarlena V. Habal
Marlena V. Habal
KTKoji Takeda
Koji Takeda
NUNir Uriel
Nir Uriel
Coronavirus disease 2019 (COVID-19) is a pandemic affecting more than 3 million people worldwide and carrying a case fatality rate exceeding 7% as of early May 2020.1 New York, New York, has emerged as the most recent epicenter of the disease, with more than 150 000 confirmed cases and nearly 11 000 fatalities (as of April 26, 2020).1 Preexisting cardiovascular diseases, such as hypertension, coronary artery disease, and diabetes, have been associated with an increased risk for COVID-19.2-4 Disease severity appears to be driven not only by viral invasion and proliferation but also by an intense immune response marked by cytokine storm, myocardial injury, and death.5,6 Recipients of heart transplant (HT) may be at an increased risk for infection and adverse outcomes with COVID-19 infection because of a number of comorbidities that are common following heart transplant, including hypertension, diabetes, and cardiac allograft vasculopathy. Moreover, while all require maintenance immunosuppression that predisposes recipients to a greater infectious risk, immunosuppression has also been theorized to be protective from cytokine storm. Preliminary case reports7,8 have not indicated a disproportionate outcome of COVID-19 on the posttransplant population, and a survey9 from China did not find an increased risk of infection among recipients of HT. In this article, we present a large case series of recipients of HT with COVID-19 and describe their presentation, disease course, outcomes, and immunosuppression management. The aim of this case series is to describe the outcomes of recipients of HT who are chronically immunosuppressed and develop COVID-19 and raise important questions about the role of the immune system in the disease process.

29 December 2021 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
MBMichael I. Brener
Michael I. Brener
AMAmirali Masoumi
Amirali Masoumi
VNVivian G. Ng
Vivian G. Ng
KTKhodr Tello
Khodr Tello
MBMarcelo Bastos
Marcelo Bastos
DBDaniel Burkhoff
Daniel Burkhoff
Right ventricular pressure-volume (PV) analysis characterizes ventricular systolic and diastolic properties independent of loading conditions like volume status and afterload. While long-considered the gold-standard method for quantifying myocardial chamber performance, it was traditionally only performed in highly specialized research settings. With recent advances in catheter technology and more sophisticated approaches to analyze PV data, it is now more commonly used in a variety of clinical and research settings. Herein, we review the basic techniques for PV loop measurement, analysis, and interpretation with the aim of providing readers with a deeper understanding of the strengths and limitations of PV analysis. In the second half of the review, we detail key scenarios in which right ventricular PV analysis has influenced our understanding of clinically relevant topics and where the technique can be applied to resolve additional areas of uncertainty. All told, PV analysis has an important role in advancing our understanding of right ventricular physiology and its contribution to cardiovascular function in health and disease.

13 May 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
DBDaniel Burkhoff
Daniel Burkhoff
VTVeli K. Topkara
Veli K. Topkara
GSGabriel Sayer
Gabriel Sayer
NUNir Uriel
Nir Uriel
This review provides a comprehensive overview of the past 25+ years of research into the development of left ventricular assist device (LVAD) to improve clinical outcomes in patients with severe end-stage heart failure and basic insights gained into the biology of heart failure gleaned from studies of hearts and myocardium of patients undergoing LVAD support. Clinical aspects of contemporary LVAD therapy, including evolving device technology, overall mortality, and complications, are reviewed. We explain the hemodynamic effects of LVAD support and how these lead to ventricular unloading. This includes a detailed review of the structural, cellular, and molecular aspects of LVAD-associated reverse remodeling. Synergisms between LVAD support and medical therapies for heart failure related to reverse remodeling, remission, and recovery are discussed within the context of both clinical outcomes and fundamental effects on myocardial biology. The incidence, clinical implications and factors most likely to be associated with improved ventricular function and remission of the heart failure are reviewed. Finally, we discuss recognized impediments to achieving myocardial recovery in the vast majority of LVAD-supported hearts and their implications for future research aimed at improving the overall rates of recovery.

17 June 2020 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
SJSneha S. Jain
Sneha S. Jain
QLQi Liu
Qi Liu
JRJayant Raikhelkar
Jayant Raikhelkar
JFJustin Fried
Justin Fried
PEPierre Elias
Pierre Elias
DAD. Edmund Anstey
D. Edmund Anstey

1 February 2020 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
NNNikhil Narang
Nikhil Narang
BCBen Chung
Ben Chung
ANAnn Nguyen
Ann Nguyen
RKRohan J. Kalathiya
Rohan J. Kalathiya
LLLuke J. Laffin
Luke J. Laffin
NUNir Uriel
Nir Uriel